Dallas, Texas – The StockGuru Spotlight – On Tuesday after market close, Lightlake Therapeutics Inc. (OTCBB: LLTP) announced that the Company is seeking to collaborate with Europe’s largest center for research and post-graduate education in psychiatry, King’s College London Institute of Psychiatry, to develop a new treatment for opiate overdose.
Shares for LLTP were up 17.5% to close out Tuesday.
In the LLTP press release with the announcement, was this comment from Dr. Roger Crystal, Chief Executive Officer of Lightlake: “We are honored to work towards partnering with the IoP in a concerted effort to create a novel treatment for opiate overdose, which is growing in prevalence worldwide due not only to the availability of street heroin but also due to the rising dependency on prescribed opioid painkillers. Recent studies show that heroin-related deaths account for around eight percent of deaths in individuals between the ages of 15 to 44 in the UK alone.”
About King’s College London
King’s College London is one of the top 30 universities in the world (2011/12 QS international world rankings), and was The Sunday Times ‘University of the Year 2010/11’, and the fourth oldest in England. A research-led university based in the heart of London, King’s has nearly 23,500 students (of whom more than 9,000 are graduate students) from nearly 140 countries, and some 6,000 employees. King’s is in the second phase of a £1 billion redevelopment programme which is transforming its estate.
King’s has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 23 departments were ranked in the top quartile of British universities; over half of our academic staff work in departments that are in the top 10 per cent in the UK in their field and can thus be classed as world leading. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly £450 million.
Read more about Lightlake Therapeutics at: http://stockguru.com//tag/lltp/
Featured This Week on StockGuru.com:
- Wednesday: Ten Tech Stocks We Like for 2012
- Thursday: Your remember the volatility of the prior Presidential election year. Will it happen again? Our analysis.
- Friday: Due Diligence Weekend: Three Stocks in Three Industries We Really Like
- Links to each feature will appear on our main page at http://stockguru.com
What is The StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worthy of our readers attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated StockGuru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected]. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: [email protected].
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. The companies that are discussed in this opinion have not approved the statements made in this release or blog post. This release or blog post contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.